Role of interleukin-32 in cancer biology

• Published in: Oncology letters Vol. 16; no. 1; pp. 41 - 47
• Main Authors: Yan, Haimeng, He, Donghua, Huang, Xi, Zhang, Enfan, Chen, Qingxiao, Xu, Ruyi, Liu, Xinling, Zi, Fuming, Cai, Zhen
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.07.2018; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Apoptosis; Breast cancer; Carcinogenesis; Chemokines; Cytokines; Disease; Gastric cancer; Gene expression; Genetic aspects; Growth factors; Health aspects; Hypoxia; Inflammation; Interleukins; Kinases; Ligands; Liver cancer; Lung cancer; Lymphoma; Medical prognosis; Metastasis; Oncology; Pancreatic cancer; Proteins; Review; Rheumatoid arthritis; Studies; Tumor necrosis factor-TNF; cancer; regulation; interleukin-32; mechanisms
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2018.8649

Interleukin-32 (IL-32), a novel proinflammatory cytokine, is highly expressed in various cancer tissues and in established cancer cell lines. IL-32 has been revealed to serve a crucial role in human cancer development, including tumour initiation, proliferation and maintenance. The expression of IL-32 is regulated by numerous factors, including genetic variations, hypoxia and acidosis in the tumour microenvironment. Understanding the underlying mechanisms of IL-32 expression and its function are critical for the discovery of novel therapeutic strategies that target IL-32. This is a review of the current literature on the regulation and function of IL-32 in cancer progression, focusing on the molecular pathways linking IL-32 and tumour development.